Amgen's Epogen
Executive Summary
FDA approves labeling change broadening the target hematocrit range to be achieved in chronic renal failure patients from 30%- 33% to 30%-36%. Amgen said the wider range will make dosing of Epogen (epoetin alfa) "more practical," but that it "will have little sales impact in the short term." Other labeling changes include clarification of dose titration guidelines, updated safety data and quality-of-life information
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth